Total Management of Cerebral Atherosclerosis

  • Sean Mullan
Conference paper


Cerebral atherosclerosis is only one aspect of a systemic disease. It is clearly recognized that coronary occlusion is a major morbidity factor in those who suffer from carotid atherosclerosis. If the neurosurgeon is to assume a role other than that of the arterial technician, then he must assume total responsibility for bringing the maximum available total treatment to his patient. Though risk factors are now well known, and methods for minimizing them are well established, most papers on surgical management of atherosclerosis do not report an optimum concomitant medical regimen.


Lipid Research Clinic Lipid Research Clinic Program Clinic Coronary Primary Prevention Trial Research Clinic Coronary Primary Prevention Cerebral Atherosclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Borhani NO (1985) Prevention of coronary heart disease in practice. JAMA 254, 2:257–264PubMedCrossRefGoogle Scholar
  2. 2.
    Keys A (1975) Coronary heart disease. Atherosclerosis 22:149–192PubMedCrossRefGoogle Scholar
  3. 3.
    Kromhout D, Bosschieter EB, Coulander D (1985) The inverse relation between fish consumption and 20-year mortality from coronary heart disease. J Engl J Med 312, 19:1205–1209CrossRefGoogle Scholar
  4. 4.
    Lieber CS (1984) To drink (moderately) or not to drink? N Engl J Med 310, 13:846–7PubMedCrossRefGoogle Scholar
  5. 5.
    Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 251, 3:351–364CrossRefGoogle Scholar
  6. 6.
    Lipid Research Clinics Program (1986) The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251, 3:365–373Google Scholar
  7. 7.
    Manson JE, Stampfer MJ, et al. (1987) Body weight and longevity: A reassessment. JAMA 257, 3:353–358PubMedCrossRefGoogle Scholar
  8. 8.
    Mettinen TA, Juttlunen JK, Kaukkarinen V, et al. (1985) Multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA 254, 15:2097–2102CrossRefGoogle Scholar
  9. 9.
    Rhoads GG, Dahlen G, Berg K, et al. (1986) Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 256, 18:2540–2544PubMedCrossRefGoogle Scholar
  10. 10.
    Schaefer EJ, Levy R (1985) Pathogenesis and management of lipoprotein disorders. In: Flier JS, (ed) Seminars in medicine of the Beth Israel Hospital, Boston. N Engl J Med 312, 20:1300-1310Google Scholar
  11. 11.
    Turpeinen O (1979) Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes. Circulation 59:1–7PubMedCrossRefGoogle Scholar
  12. 12.
    Vartiainen I, Kanerva K (1947) Arteriosclerosis and war-time. Ann Med Fenn 36, 3:748–758Google Scholar
  13. 13.
    Vega GL, Grundy SC (1987) Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA 257, 1:33–38PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1988

Authors and Affiliations

  • Sean Mullan
    • 1
  1. 1.Department of NeurosurgeryUniversity of Chicago Medical CenterChicagoUSA

Personalised recommendations